![](/img/cover-not-exists.png)
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Desai, Jayesh, Gan, Hui, Barrow, Catherine, Jameson, Michael, Atkinson, Victoria, Haydon, Andrew, Millward, Michael, Begbie, Stephen, Brown, Michael, Markman, Ben, Patterson, William, Hill, Andrew, HoLanguage:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.19.02654
Date:
March, 2020
File:
PDF, 791 KB
english, 2020